Dermata Therapeutics, Inc.
Moat Score — Dermata Therapeutics, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Dermata holds an issued U.S. patent (12,208,123) and an Australian patent on its Clearing Treatment formulation, plus pending patent families on botulinum-toxin delivery, clinical methods, and dermal fillers expiring 2039-2041. However, the company itself acknowledges these device/formulation patents are 'more limited' than patents on novel chemical structures, and its positive Phase 3 STAR-1 data for the abandoned XYNGARI candidate no longer protects a commercialized drug. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Dermata has no manufacturing scale or cost edge; it owns no manufacturing facilities and depends entirely on third-party manufacturers. It is also fully dependent on a single supplier, Reka-Farm, for its Spongilla lacustris raw material, which is a cost and supply-chain vulnerability rather than an advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | As a pre-revenue company about to launch its first consumer skincare products (Tome Foundational and Clearing Treatments), Dermata has no demonstrated pricing power. It will compete against OTC acne/skincare staples (Neutrogena, CeraVe, Differin) and lower-cost generics that compete largely on price, limiting near-term ability to command premium pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Dermata's Bioneedle-based skincare and dermatology products exhibit no network effects; value to one consumer or clinician does not increase as more people use Tome products or the Bioneedle delivery platform. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Topical OTC skincare routines create only modest switching costs; consumers can readily substitute Tome's weekly Bioneedle treatments for competing OTC acne or skin-renewal products from Neutrogena, Curology, or Hims & Hers with minimal friction, though a recommended 12-week treatment cycle could create some mild routine-based retention. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The global OTC skincare/acne market is large (estimated to reach $736 billion by 2028) and crowded with large, well-capitalized incumbents and DTC platforms, meaning Dermata is not protected by a niche market too small to attract competition; it is instead a small new entrant facing scale disadvantages, not an efficient-scale moat. |